The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - BioNTech (I); GANYMED Pharmaceuticals
Leadership - BioNTech (I); GANYMED Pharmaceuticals
Stock and Other Ownership Interests - BioNTech (I)
Consulting or Advisory Role - GANYMED Pharmaceuticals (I)
Patents, Royalties, Other Intellectual Property - BioNTech (I); GANYMED Pharmaceuticals
 
Employment - Astellas Pharma
Stock and Other Ownership Interests - Genentech; Rigel
Consulting or Advisory Role - AstraZeneca; HERON; Johnson & Johnson
Research Funding - Ironwood Pharmaceuticals (I)

Health-related quality-of-life (HRQoL) results from the FAST study: A phase II trial of epirubicin, oxaliplatin, and capecitabine with or without IMAB362 in patients with advanced CLDN18.2+ gastric and gastroesophageal junction adenocarcinoma.
 
Robert Morlock
No Relationships to Disclose
 
James Turnbull
No Relationships to Disclose
 
Steven Blahut
No Relationships to Disclose
 
Michelle R Krukas-Hampel
Employment - QuintilesIMS
Consulting or Advisory Role - Astellas Pharma (Inst)
 
Emily Hawryluk
Employment - QuintilesIMS
Stock and Other Ownership Interests - QuintilesIMS
 
Özlem Tureci
No Relationships to Disclose